HN2011000072A - Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c - Google Patents

Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c

Info

Publication number
HN2011000072A
HN2011000072A HN2011000072A HN2011000072A HN2011000072A HN 2011000072 A HN2011000072 A HN 2011000072A HN 2011000072 A HN2011000072 A HN 2011000072A HN 2011000072 A HN2011000072 A HN 2011000072A HN 2011000072 A HN2011000072 A HN 2011000072A
Authority
HN
Honduras
Prior art keywords
macrociclic
hepatitis
virus
indol
derivatives
Prior art date
Application number
HN2011000072A
Other languages
English (en)
Inventor
Marie Helene Vendeville Sandrine
Jean Marie Bernard Raboisson Pierre
Lin Abdellah Tahri Tse-I
Ingrid Eduard Amssoms Katie
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of HN2011000072A publication Critical patent/HN2011000072A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

ESTA INVENCION SE REFIERE A DERIVADOS DE INDOL MACROCICLICOS QUE TIENEN ACTIVIDAD INHIBIDORA SOBRE LA REPLICACION DEL VIRUS DE LA HEPATITIS C (HCV). TAMBIEN SE REFIERE A COMPOSICIONES QUE COMPRESNDEN ESTOS COMPUESTOS COMO INGREDIENTES ACTIVOS, ASI COMO A PROCESOS PARA PREPARAR ESTOS COMPUESTOS Y COMPOSICIONES.
HN2011000072A 2008-07-08 2011-01-07 Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c HN2011000072A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08159965 2008-07-08
EP08160254 2008-07-11
EP08161743 2008-08-04

Publications (1)

Publication Number Publication Date
HN2011000072A true HN2011000072A (es) 2013-09-01

Family

ID=40972916

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2011000072A HN2011000072A (es) 2008-07-08 2011-01-07 Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c

Country Status (32)

Country Link
US (2) US8921355B2 (es)
EP (1) EP2310396B1 (es)
JP (2) JP5426671B2 (es)
KR (1) KR101640374B1 (es)
CN (1) CN102089314B (es)
AP (1) AP2743A (es)
AR (1) AR072726A1 (es)
AU (1) AU2009267389B8 (es)
BR (1) BRPI0915887B8 (es)
CA (1) CA2729307C (es)
CL (1) CL2011000032A1 (es)
CO (1) CO6351793A2 (es)
CR (1) CR20110076A (es)
DK (1) DK2310396T3 (es)
EA (1) EA019008B1 (es)
EC (1) ECSP11010750A (es)
ES (1) ES2651038T3 (es)
HK (1) HK1155734A1 (es)
HN (1) HN2011000072A (es)
HR (1) HRP20171892T1 (es)
HU (1) HUE035244T2 (es)
IL (1) IL210086A (es)
LT (1) LT2310396T (es)
MX (1) MX2011000276A (es)
NI (1) NI201100010A (es)
NO (1) NO2310396T3 (es)
NZ (2) NZ603343A (es)
SI (1) SI2310396T1 (es)
SV (1) SV2011003796A (es)
TW (1) TWI454476B (es)
UY (1) UY31973A (es)
WO (1) WO2010003658A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0821836A2 (pt) 2007-12-24 2015-06-16 Tibotec Pharm Ltd Indóis macrocíclicos como inibidores do vírus da hepatite c
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
UA108211C2 (uk) * 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
SG184524A1 (en) * 2010-04-13 2012-11-29 Janssen Pharmaceuticals Inc Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
MX2012015198A (es) 2010-06-24 2013-02-11 Janssen R & D Ireland Preparacion de acido 13-ciclohexil-3-metoxi-6-[metil-(2-{2-[metil- (sulfamoil)-amino]-etoxi}-etil)-carbomoil]-7h-indolo-[2,1-a]-[2]- benzazepin-10-carboxilico.
IN2014DN02346A (es) 2011-09-02 2015-05-15 Novartis Ag
US8716275B2 (en) * 2011-10-20 2014-05-06 Bristol-Myers Squibb Company Compound for the treatment of hepatitis C
WO2014033668A2 (en) 2012-08-31 2014-03-06 Janssen Pharmaceuticals, Inc. Combination of a macrocyclic protease inhibitor of hcv, a non-nucleoside hcv inhibitor and ritonavir
WO2014152275A1 (en) * 2013-03-14 2014-09-25 Concert Pharmaceuticals, Inc. Deuterium modified derivatives of the ns5b polymerase inhibitor tmc647055
US10450263B2 (en) 2017-02-10 2019-10-22 Southern Research Institute Benzo annulenes as antiviral agents
KR101974388B1 (ko) 2017-06-23 2019-05-02 (주)에니켐텍 알킬 디에틸렌 트리아민 유도체 및 이의 제조방법
US11066357B2 (en) 2017-12-26 2021-07-20 Southern Research Institute Benzoannulene derivatives as antiviral agents

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5807876A (en) * 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) * 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US20050267836A1 (en) * 1996-03-25 2005-12-01 Cfph, Llc Method and system for transacting with a trading application
CN1116288C (zh) 1996-04-23 2003-07-30 沃泰克斯药物股份有限公司 用作肌苷－5'－一磷酸脱氢酶抑制剂的脲衍生物
AU6701598A (en) 1997-03-14 1998-09-29 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
SK13332001A3 (sk) 1999-03-19 2002-02-05 Vertex Pharmaceuticals Incorporated Inhibítory IMPDH enzýmu a ich použitie
WO2002019369A1 (fr) 2000-08-30 2002-03-07 Matsushita Electric Industrial Co., Ltd. Unite d'affichage a plasma et son procede de fabrication
EP1713822B1 (en) 2004-01-30 2010-03-17 Medivir AB Hcv ns-3 serine protease inhibitors
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
TW200800225A (en) 2005-09-02 2008-01-01 Tibotec Pharm Ltd Benzodiazepines as HCV inhibitors
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
GB0522881D0 (en) 2005-11-10 2005-12-21 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2007092000A1 (en) 2006-02-06 2007-08-16 Bristol-Myers Squibb Company Inhibitors of hcv replication
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) * 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521442B2 (en) * 2006-05-25 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
ATE493428T1 (de) 2006-10-10 2011-01-15 Medivir Ab Hcv-nukleosidinhibitor
US8101595B2 (en) 2006-12-20 2012-01-24 Istituto di Ricerche di Biologia Molecolare P. Angletti SpA Antiviral indoles
WO2009010785A1 (en) * 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis c infections
TWI454476B (zh) * 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
TW201023858A (en) 2008-09-18 2010-07-01 Ortho Mcneil Janssen Pharm Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside
KR101868412B1 (ko) 2009-02-27 2018-06-18 얀센 파마슈티칼스 인코포레이티드 Ｈｃｖ 마크로사이클릭 저해제의 무정형 염
SG184524A1 (en) 2010-04-13 2012-11-29 Janssen Pharmaceuticals Inc Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
MX2012015198A (es) 2010-06-24 2013-02-11 Janssen R & D Ireland Preparacion de acido 13-ciclohexil-3-metoxi-6-[metil-(2-{2-[metil- (sulfamoil)-amino]-etoxi}-etil)-carbomoil]-7h-indolo-[2,1-a]-[2]- benzazepin-10-carboxilico.
WO2014033668A2 (en) 2012-08-31 2014-03-06 Janssen Pharmaceuticals, Inc. Combination of a macrocyclic protease inhibitor of hcv, a non-nucleoside hcv inhibitor and ritonavir

Also Published As

Publication number Publication date
BRPI0915887A2 (pt) 2015-11-03
US9427440B2 (en) 2016-08-30
HK1155734A1 (en) 2012-05-25
JP2014028818A (ja) 2014-02-13
LT2310396T (lt) 2017-12-27
MX2011000276A (es) 2011-03-02
NZ603343A (en) 2013-08-30
EP2310396A1 (en) 2011-04-20
JP2011527299A (ja) 2011-10-27
AR072726A1 (es) 2010-09-15
NO2310396T3 (es) 2018-02-03
UY31973A (es) 2010-01-29
TW201014865A (en) 2010-04-16
CA2729307A1 (en) 2010-01-14
HUE035244T2 (hu) 2018-05-02
DK2310396T3 (en) 2017-12-11
HRP20171892T1 (hr) 2018-01-12
EA019008B1 (ru) 2013-12-30
AU2009267389B8 (en) 2013-07-04
US20140107101A1 (en) 2014-04-17
JP5426671B2 (ja) 2014-02-26
CL2011000032A1 (es) 2011-07-15
KR20110040889A (ko) 2011-04-20
ES2651038T3 (es) 2018-01-23
TWI454476B (zh) 2014-10-01
AP2010005521A0 (en) 2010-12-31
CR20110076A (es) 2011-11-10
WO2010003658A1 (en) 2010-01-14
JP5808370B2 (ja) 2015-11-10
KR101640374B1 (ko) 2016-07-18
CN102089314A (zh) 2011-06-08
NZ590073A (en) 2012-11-30
SI2310396T1 (en) 2018-01-31
EA201170153A1 (ru) 2011-08-30
AU2009267389B2 (en) 2013-05-30
CO6351793A2 (es) 2011-12-20
AU2009267389A8 (en) 2013-07-04
CN102089314B (zh) 2014-07-23
ECSP11010750A (es) 2011-08-31
AU2009267389A1 (en) 2010-01-14
EP2310396B1 (en) 2017-09-06
IL210086A0 (en) 2011-02-28
CA2729307C (en) 2017-08-29
BRPI0915887B8 (pt) 2021-05-25
US20110105473A1 (en) 2011-05-05
IL210086A (en) 2014-05-28
SV2011003796A (es) 2011-04-08
AP2743A (en) 2013-09-30
NI201100010A (es) 2011-09-07
BRPI0915887B1 (pt) 2020-02-18
US8921355B2 (en) 2014-12-30

Similar Documents

Publication Publication Date Title
HN2011000072A (es) Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c
EA201000089A1 (ru) Применение гомо- и сополимеров для стабилизации составов активных ингредиентов
CR11316A (es) Derivado de uracilo o timina para el tratamiiento de la hepatitis c.
ECSP099685A (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
CL2016001580A1 (es) Uso de compuestos derivados de indol para tratar una infección por flavivirus; compuestos derivados de indol; composiciones farmacéuticas; y uso de una combinación.
DOP2013000185A (es) Compuestos antivirales
GT200900027A (es) Compuestos organicos
EA201270555A1 (ru) Комбинации ингибиторов вируса гепатита с
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
HN2012001162A (es) Triazolopiridinas
PE20151423A1 (es) Derivados tetrahidropiranilo inhibidores del hcv
HN2010002733A (es) Compuestos y composiciones como inhibidores de cinasa
CL2010001634A1 (es) Compuestos derivados de nucleosidos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que los comprende; y combinacion farmaceutica.
CL2012001176A1 (es) Compuestos derivados de bencimidazol-imidazol, inhibidores del virus de la hepatitis c (hcv); composición farmacéutica que los comprende; combinación farmacéutica; uso en la prevención o tratamiento de infección de hcv.
HN2008001191A (es) Compuestos de biciclolactama sustituida
CR20110043A (es) Mezclas fungicidas que comprenden 1-metilpirazol-4-ilcarboxanilidas sustituidas
CR11583A (es) Arilpirrolinas insecticidas
UY32659A (es) Pirazinilpirazoles
NI201100056A (es) Compuestos de multiheteroarilo como inhibidores de prostaglandina d sintasa hematopoyética y su uso para tratar enfermedades mediadas por prostaglandina d2.
CL2011001364A1 (es) Compuestos derivados de nucleotidos de uracil ciclopropilicos, inhibidores de la polimerasa del virus de la hepatitis c; composiciones farmaceuticas; y uso del compuesto para el tratamiento de hepatitis c (hcv).
DOP2016000253A (es) Nuevos compuestos
HN2009000566A (es) Nuevos derivados de diosmetina, su procedimiento de prearacion y las composiciones farmaceuticas que lo contienen.
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
UY32721A (es) Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados